Fractyl Health GUTS 深 滬
等待開盤 07-24 09:30:00 美东时间
0.7567
-0.001
-0.17%
華盛通- 最 高0.7777
- 今 開0.758
- 成交量 224.30万股
- 最 低 0.73
- 昨 收 0.758
- 總市值 1.20亿
- 52周最高 2.445
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 0.3772
- 委 比 83.33%
- 總股本 1.59亿
- 歷史最高 14.50
- 量 比 1.01
- 振 幅 6.29%
- 歷史最低 0.3772
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | AI数据中心需求引爆订单！AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购
Lucid劲升近29%！聘请重组顾问扭转经营颓势；AI数据中心需求引爆订单，AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购>>
07-16 19:21
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health Inc. (NASDAQ:GUTS) reported Wednesday one-year results from the Midpoint Cohort of its REMAIN-1 study, saying a single treatment with its investigational Revita DMR System helped patients maintain more of their GLP-1-induced weight loss than a sham procedure. The clinical-stage metabo...
07-16 02:22
Fractyl gains as Revita procedure reduces weight gain in post-GLP-1 setting
Fractyl Health (GUTS) added ~9% in the morning trading on Wednesday after the metabolic therapeutics company said that its Revita procedure reduced weight regain by roughly 40% following GLP-1 discont...
07-15 22:48
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
Fractyl Health announced positive one-year results from its REMAIN-1 Midpoint Cohort, showing that Revita maintained 84% of GLP-1-induced weight loss versus 46% with sham in patients with complete duodenal ablation. The procedure demonstrated excellent tolerability with no serious adverse events. Key findings include dose-dependent durability, greater benefit for high-need patients, and a 91% weight-maintenance responder rate in optimized populat...
07-15 10:00
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
Fractyl Health Announces 1-Yr Results From Open-Label REVEAL-1 Cohort; Participants Retained ~78% Of GLP-1 Induced Total Body Weight Loss One Year After Discontinuation And Single Revita Procedure
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure5.3% mean weight change observed with Revita (n=15); published third-party studies after
06-04 19:06
Fractyl Health Q1 2026 Earnings Call: Complete Transcript
Fractyl Health (NASDAQ:GUTS) held its first-quarter earnings conference call on...
05-13 05:26
Fractyl Health Q1 EPS $0.06 Beats $(0.16) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.16) by 137.5 percent. This is a 112.24 percent increase over losses of $(0.49) per share from
05-13 04:13
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Fractyl Health Receives Clinical Trial Application Authorization In Netherlands To Initiate Phase 1/2 First-in-human Study Of RJVA-001, Expects To Start Dosing And Report Preliminary Data In 2H of 2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita in pivotal development for post-GLP-1 weight maintenance and Rejuva entering first-in-human studies for type 2 diabetesFirst-in-human
05-11 19:06
